Big money is funding a new class of diagnostics that may predict our disease long before it is expressed. While reimbursement presents traditional barriers to those on the bleeding edge, the value of the predictive indicator data these companies are amassing may dwarf the need for it. Talk with leaders about how diagnostics are driving new insights and may be the next AI dark horse.
Host: Sue Siegel, former Chief Innovation Officer & CEO, GE Ventures, GE
Chad Robins, Co-Founder & CEO, Adaptive Biotechnologies
Mike Pellini, MD, Managing Partner, Section 32; Chairman, Foundation Medicine
Kim Popovits, President & CEO, Genomic Health
Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare Full bio ›
Mr. Robins is Adaptive’s Chief Executive Officer and Co-founder. He has held executive-level positions in real estate, investment banking, private equity and medical technology. In 2012, Mr. Robins was a “40 Under 40” Seattle Leaders honoree. In 2015, he and his brother, Harlan Robins, were honored as one of Goldman Sachs 100 Most Intriguing Entrepreneurs of the Year. Mr. Robins was a finalist Full bio ›
Sue Siegel is GE’s Former Chief Innovation Officer and CEO of GE Ventures, leading the development and acceleration of innovation across GE. She has 35+ years of corporate, entrepreneurial and venture capital experience all geared towards turning untapped potential into real value. In this role, Sue led the launch of GE Ventures, a multimodal in Full bio ›